ProCE Banner Activity

Evolution in the Care of NSCLC: Keeping Pace With Today’s Best Practices

Multimedia
Watch this CME-certified on-demand Webcast of a CCO symposium from ASCO 2019 where experts discuss best practices in the rapidly evolving treatment paradigm across advanced NSCLC.

Released: July 08, 2019

Expiration: July 06, 2020

No longer available for credit.

Share

Faculty

Edward S. Kim

Edward S. Kim, MD

Chief, Section of Head and Neck Medical Oncology
Associate Professor, Thoracic/Head and Neck Medical Oncology
University of Texas M. D. Anderson Cancer Center
Houston, Texas

Zofia Piotrowska

Zofia Piotrowska, MD

Assistant Professor of Medicine
Massachusetts General Hospital Cancer Center
Harvard Medical School
Boston, Massachusetts

Suresh S. Ramalingam

Suresh S. Ramalingam, MD

Associate Professor
Director,
Division of Medical Oncology
Emory University, Winship Cancer Institute
Atlanta, Georgia

H. Jack West

H. Jack West, MD

Medical Director
Thoracic Oncology Program
Swedish Cancer Institute
Seattle, Washington

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

AstraZeneca

Faculty Disclosure

Primary Author

Edward S. Kim, MD

Chief, Section of Head and Neck Medical Oncology
Associate Professor, Thoracic/Head and Neck Medical Oncology
University of Texas M. D. Anderson Cancer Center
Houston, Texas

Edward S. Kim, MD, FACP, has disclosed that he has received consulting fees from AstraZeneca, Boehringer Ingelheim, Genentech, Lilly, Merck, and Takeda and funds for research support from AstraZeneca, Genentech, Lilly, and Takeda.

Zofia Piotrowska, MD

Assistant Professor of Medicine
Massachusetts General Hospital Cancer Center
Harvard Medical School
Boston, Massachusetts

Zofia Piotrowska, MD, MHS, has disclosed that she has received consulting fees from AstraZeneca, Guardant Health, ImmunoGen, Spectrum, and Takeda and funds for research support from AstraZeneca, Novartis, Spectrum, and Takeda.

Suresh S. Ramalingam, MD

Associate Professor
Director,
Division of Medical Oncology
Emory University, Winship Cancer Institute
Atlanta, Georgia

Suresh S. Ramalingam, MD, has disclosed that he has received consulting fees from Amgen, AstraZeneca, Bristol-Myers Squibb, Genentech, Loxo, Merck, Nektar, Tesaro, and Takeda and funds for research support from AstraZeneca, Bristol-Myers Squibb, Merck, and Syndax.

H. Jack West, MD

Medical Director
Thoracic Oncology Program
Swedish Cancer Institute
Seattle, Washington

H. Jack West, MD, has disclosed that he has received consulting fees from Ariad/Takeda, Bristol-Myers Squibb, Celgene, Genentech/Roche, and Merck and fees for non-CME/CE services from Ariad/Takeda, Genentech/Roche, Lilly, and Merck.

Staff Disclosure

Staff

Rachael M. Andrie, PhD

Clinical Editor

Rachael M. Andrie, PhD, has no relevant conflicts of interest to report.

Tiffany Hensley-McBain, PhD

Clinical Editor

Tiffany Hensley-McBain, PhD, has no relevant conflicts of interest to report.

Gordon Kelley,

Clinical Editor
Clinical Care Options, LLC

Gordon Kelley has no relevant conflicts of interest to report.

Jim Mortimer,

Product Director, Hematology/Oncology
Clinical Care Options, LLC

Jim Mortimer has reported that his spouse has ownership interest in and has received salary from AstraZeneca.

Kevin Obholz, PhD

Editorial Director, Hematology/Oncology

Kevin Obholz, PhD, has no relevant conflicts of interest to report.

Timothy A. Quill, PhD

Senior Managing Editor

Timothy A. Quill, PhD, has no relevant conflicts of interest to report.

Tina B. Stacy, PharmD, FACEHP, BCOP, CHCP

Executive Vice President, Educational Strategy
General Manager, Oncology

Tina B. Stacy, PharmD, FACEHP, BCOP, CHCP, has no relevant conflicts of interest to report.